What is DLB's health score?

Dolby Laboratories, Inc. (DLB) has a TradeApes health score of 62 out of 100, rated Healthy. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is DLB's estimated fair value?

Based on our 5-year discounted cash flow model, Dolby Laboratories, Inc.'s estimated fair value is $27.74 per share, representing a -48.2% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is DLB undervalued or overvalued?

Our model currently rates DLB as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for DLB... Refresh in a moment for the full analysis.

Dolby Laboratories, Inc. (DLB)

Financials Overvalued medium healthy

$53.53

Updated: 2026-06-05

TradeApes Score

Financial Strength

80 Strong

Operating Trend

58 Mixed

Relative Value

55 Mixed

Capital Allocation

40 Weak

Risk

80 Strong

Est. Fair Value $27.74

DCF Upside -48.2%

Sector Rank #5309 of 6303

Key Findings

+ Net cash position — more cash on hand than total debt

Unlock Full Report →

− Above historical median — trading above its own valuation average

Unlock Full Report →

2 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.